Arcturus Therapeutics (NASDAQ:ARCT) Research Coverage Started at Roth Mkm

Roth Mkm began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price target on the biotechnology company’s stock.

Several other analysts have also issued reports on ARCT. Zacks Research lowered shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Guggenheim cut shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. HC Wainwright cut their price objective on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Wednesday. Finally, BTIG Research lowered their target price on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Arcturus Therapeutics Trading Down 0.8%

ARCT opened at $7.53 on Thursday. Arcturus Therapeutics has a 1-year low of $5.85 and a 1-year high of $24.17. The company’s fifty day moving average price is $6.81 and its two-hundred day moving average price is $12.60. The company has a market cap of $213.93 million, a price-to-earnings ratio of -3.06 and a beta of 2.24.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative return on equity of 28.68% and a negative net margin of 68.35%.The business had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $17.47 million. As a group, equities analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio purchased a new stake in Arcturus Therapeutics in the 2nd quarter worth $240,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Arcturus Therapeutics by 6.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,947,835 shares of the biotechnology company’s stock worth $35,899,000 after purchasing an additional 115,368 shares during the last quarter. Corton Capital Inc. purchased a new stake in shares of Arcturus Therapeutics in the second quarter worth about $174,000. Y Intercept Hong Kong Ltd boosted its stake in Arcturus Therapeutics by 92.5% during the second quarter. Y Intercept Hong Kong Ltd now owns 44,432 shares of the biotechnology company’s stock valued at $578,000 after buying an additional 21,355 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in Arcturus Therapeutics by 67.0% during the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,385 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 10,188 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.